Peer-Reviewed Publication
JAMA Netw Open2026;9(9):e2635753.September 1, 2026Journal Article
A Digital Therapeutic Intervention for Negative Symptoms of Schizophrenia: A Randomized Clinical Trial.
Abhishek Pratap1, Shaheen E Lakhan2, Cassandra Snipes2, Wenbo Tang3, Olya Besedina4, Faith Dickerson5, René S Kahn6, Jean-Pierre Lindenmayer7, Jamie Winderbaum Fernandez8, Greg W Mattingly9, John Torous10, Gregory P Strauss11, Austin Speier12, Christoph von der Goltz13, Cornelia Dorner-Ciossek14
1Global Clinical Development Mental Health and Eye Health, Boehringer Ingelheim Pharmaceuticals Inc, Ridgefield, Connecticut.
2Medical & Clinical Development Department, Click Therapeutics Inc, New York, New York.
3Global Biostatistics & Data Sciences, Boehringer Ingelheim Pharmaceuticals Inc, Ridgefield, Connecticut.
4Biostatistics Department, Click Therapeutics Inc, New York, New York.
5Psychology, Research and Education, Sheppard Pratt Health System, Towson, Maryland.
6Department of Psychiatry and Behavioral Health System, Icahn School of Medicine at Mount Sinai, New York, New York.
7Psychopharmacology Research Unit, New York University, New York, New York.
8Interventional Psychiatry of Tampa Bay Clinical Research, Tampa, Florida.
9Department of Psychiatry, Washington University, St Louis, Missouri.
10Division of Digital Psychiatry, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts.
11Department of Psychology, University of Georgia, Athens, Georgia.
12Regulatory Department, Click Therapeutics Inc, New York, New York.
13Global Clinical Development Mental Health and Eye Health, Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany.
14Neuroscience & Mental Health Discovery Research, Boehringer Ingelheim Pharma GmbH & Co KG, Ingelheim am Rhein, Germany.
Abstract
IMPORTANCE: Negative symptoms of schizophrenia are a major contributor to poor outcomes, yet no US Food and Drug Administration-approved pharmacotherapies are specifically indicated for their treatment. In particular, motivation and pleasure negative symptoms are especially burdensome for patients. Psychosocial interventions can be effective, but access barriers and challenges in sustaining engage…
Create a free account to keep reading
Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.
Want unlimited research access? See Pro plans